129.84
1.32 (1.03%)
| 前收盘价格 | 128.52 |
| 收盘价格 | 127.50 |
| 成交量 | 434,971 |
| 平均成交量 (3个月) | 756,522 |
| 市值 | 4,437,194,240 |
| 市盈率 (P/E TTM) | 51.12 |
| 预期市盈率 (P/E Forward) | 60.61 |
| 价格/销量 (P/S) | 9.38 |
| 股市价格/股市净资产 (P/B) | 10.16 |
| 52周波幅 | |
| 利润日期 | 24 Feb 2026 |
| 营业毛利率 | 10.03% |
| 营业利益率 (TTM) | 19.12% |
| 稀释每股收益 (EPS TTM) | 1.42 |
| 季度收入增长率 (YOY) | 48.20% |
| 季度盈利增长率 (YOY) | 110.60% |
| 总债务/股东权益 (D/E MRQ) | 194.67% |
| 流动比率 (MRQ) | 9.10 |
| 营业现金流 (OCF TTM) | 49.38 M |
| 杠杆自由现金流 (LFCF TTM) | -84.81 M |
| 资产报酬率 (ROA TTM) | 4.21% |
| 股东权益报酬率 (ROE TTM) | 22.99% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 混合的 | 看跌 |
| Medical Devices (全球的) | 混合的 | 看跌 | |
| 股票 | TransMedics Group, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 4.0 |
| 内部交易活动 | -2.5 |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.60 |
|
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Small Growth |
| 内部持股比例 | 3.03% |
| 机构持股比例 | 121.56% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 175.00 (Oppenheimer, 34.78%) | 购买 |
| 中 | 160.00 (23.23%) | |
| 低 | 130.00 (Stifel, 0.12%) | 保留 |
| 平均值 | 158.00 (21.69%) | |
| 总计 | 5 购买, 2 保留 | |
| 平均价格@调整类型 | 130.85 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Stifel | 09 Mar 2026 | 130.00 (0.12%) | 保留 | 134.77 |
| Evercore ISI Group | 25 Feb 2026 | 170.00 (30.93%) | 购买 | 131.85 |
| JP Morgan | 25 Feb 2026 | 149.00 (14.76%) | 保留 | 131.85 |
| Needham | 25 Feb 2026 | 174.00 (34.01%) | 购买 | 131.85 |
| Oppenheimer | 25 Feb 2026 | 175.00 (34.78%) | 购买 | 131.85 |
| Piper Sandler | 25 Feb 2026 | 160.00 (23.23%) | 购买 | 131.85 |
| Canaccord Genuity | 17 Dec 2025 | 148.00 (13.99%) | 购买 | 121.93 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| CORCORAN NICHOLAS | - | 147.00 | -2,966 | -436,002 |
| HERNANDEZ GERARDO | - | 147.33 | -7,611 | -1,123,593 |
| LOVELL STEPHANIE | - | 147.66 | -1,193 | -176,158 |
| RANGANATH ANIL P. | - | 147.00 | -864 | -127,008 |
| WEILL DAVID | - | 147.66 | -3,571 | -527,294 |
| 累积净数量 | -16,205 | |||
| 累积净值 ($) | -2,390,055 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 147.33 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| HERNANDEZ GERARDO | 职员 | 04 Mar 2026 | 卖 (-) | 7,236 | 147.66 | 1,068,468 |
| HERNANDEZ GERARDO | 职员 | 04 Mar 2026 | 执行期权 | 7,236 | - | - |
| WEILL DAVID | 董事 | 04 Mar 2026 | 卖 (-) | 3,571 | 147.66 | 527,294 |
| WEILL DAVID | 董事 | 04 Mar 2026 | 执行期权 | 3,571 | - | - |
| LOVELL STEPHANIE | 董事 | 04 Mar 2026 | 卖 (-) | 1,193 | 147.66 | 176,158 |
| CORCORAN NICHOLAS | 职员 | 02 Mar 2026 | 卖 (-) | 2,966 | 147.00 | 436,002 |
| RANGANATH ANIL P. | 职员 | 02 Mar 2026 | 卖 (-) | 864 | 147.00 | 127,008 |
| HERNANDEZ GERARDO | 职员 | 02 Mar 2026 | 卖 (-) | 375 | 147.00 | 55,125 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合